1705 completed, 715 unknown, 668 recruiting, 609 terminated. 4471 Phase 2, 1014 Phase 1, 122 Phase 3.
Follow Thoracic Neoplasms: new trials by email Literature Review of Thoracic Neoplasms trials Research Report on Thoracic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation RC48-ADC, Pyrotinib - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | RemeGen Co., Ltd. | 26 | 2027-12-01 | 2026-09-22 |
| Antigen-specific T Cells Against Lung Cancer Lung cancer-specific T cells - Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 20 | 2027-06-01 | 2026-11-02 |
| Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRI Hyperpolarized xenon MRI - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Not yet recruiting | Xemed LLC | 10 | 2027-03-01 | 2026-09-01 |
| A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas Sacituzumab Tirumotecan (Sac-TMT) - Unresectable Thymic Carcinoma | Phase 2 | Not yet recruiting | National Cancer Center, Japan | 35 | 2027-02-01 | 2026-08-06 |
| Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced, Non-small Cell Lung Cancer NHT102, DryNeb - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 / Phase 2 | Not yet recruiting | Nob Hill Therapeutics, Inc. | 100 | 2027-01-11 | 2026-10-08 |
| Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer Lurbinectedin, Osimertinib - Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Misty Shields | 16 | 2027-01-01 | 2026-10-15 |
| Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 Cemiplimab, Adjuvant chemotherapy - Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Henry Ford Health System | 33 | 2027-01-01 | 2026-07-15 |
| Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung Cancer LND101, Carboplatin, Pemetrexed - Non Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Canadian Cancer Trials Group | 160 | 2026-12-31 | 2026-10-27 |
| Testing Repeat Radiation Therapy for Recurrent Non-small Cell Lung Cancer Biospecimen Collection, Computed Tomography, Immunotherapy - Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8 | Phase 2 | Not yet recruiting | NRG Oncology | 138 | 2026-12-18 | 2026-09-23 |
| A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer Investigator Choice Immunotherapy (for example: pembrolizumab, cemiplimab, durvalumab, ipilimumab plus nivolumab), Investigator Choice Chemotherapy (for example docetaxel with or without ramucirumab, gemcitabine, or other National Comprehensive Cancer Network (NCCN)-recommended treatments), Ablative Hypofractionated Radiotherapy - Non-Small Cell Lung Cancer, Metastatic Lung Cancer | Phase 2 | Recruiting | University of Chicago | 39 | 2026-12-12 | 2026-06-16 |
| 3-Dimensional Virtual Reality Modelling With Intravascular Indocyanine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection Trial 3-Dimensional VR Modelling (Elucis) with Intravascular Indocyanine Green Fluorescence Mapping, 3-Dimensional Modelling (Synapse 3D) with Intravascular Indocyanine Green Fluorescence Mapping - Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | St. Joseph's Healthcare Hamilton | 89 | 2026-12-01 | 2026-02-02 |
| A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation LG00313112 - Ovarian Cancer, Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | LG Chem | 250 | 2026-12-01 | 2026-08-07 |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI) Radiotherapy - Metastatic NSCLC - Non-Small Cell Lung Cancer, OligoProgressive Metastatic Disease | Phase 2 | Not yet recruiting | University Health Network, Toronto | 60 | 2026-12-01 | 2026-11-04 |
| A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220) Pumitamig, Carboplatin, Cisplatin - Early-Stage Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Bristol-Myers Squibb | 80 | 2026-11-30 | 2026-10-13 |
| A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC Lurbinectedin, Durvalumab - Extensive-stage Small-cell Lung Cancer | Phase 2 | Recruiting | Jazz Pharmaceuticals | 50 | 2026-11-30 | 2026-09-17 |
| A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Investigational drug: HLX37 dose1, IV, Q3W, PEMBROLIZUMAB (alone or when added to a regimen above), Carboplatin (Investigator discretion) - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 / Phase 3 | Not yet recruiting | Shanghai Henlius Biotech | 1438 | 2026-11-30 | 2026-10-08 |
| Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors REGN13089-M404-M2980 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 320 | 2026-11-23 | 2026-10-07 |
| Becotatug Vedotin + Pucotenlimab+Platinum Induction and Sequential CCRT for Unresectable LA NSCLC Becotatug Vedotin (MRG003)+pucotenlimab+platinum, radiotherapy - Non-Small Cell Carcinoma of Lung, Locally Advanced | Phase 2 | Not yet recruiting | Sun Yat-sen University | 24 | 2026-11-15 | 2026-10-20 |
| Low-Dose Radiotherapy Plus Adebrelimab and Chemotherapy for Extensive-Stage Small Cell Lung Cancer Adebrelimab + Chemotherapy + Radiotherapy - Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 25 | 2026-11-15 | 2026-11-04 |
Showing 20 of 4471. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (3130) · Lung Neoplasms (1421) · Small Cell Lung Carcinoma (579) · Breast Neoplasms (212) · Neoplasms (210) · Colorectal Neoplasms (195) · Neoplasm Metastasis (191) · Adenocarcinoma of Lung (190) · Melanoma (185) · Mesothelioma, Malignant (165) · Ovarian Neoplasms (145) · Pancreatic Neoplasms (139) · Brain Neoplasms (126) · Squamous Cell Carcinoma of Head and Neck (119) · Stomach Neoplasms (119)
Neoplasms by Site (4451) · Respiratory Tract Neoplasms (4381) · Respiratory Tract Diseases (4345) · Lung Diseases (4297) · Neoplasms (4261) · Carcinoma, Bronchogenic (3596) · Bronchial Neoplasms (3594) · Lung Neoplasms (2957) · Neoplasms by Histologic Type (970) · Neoplasms, Glandular and Epithelial (810) · Carcinoma (563) · Digestive System Diseases (409) · Digestive System Neoplasms (403) · Skin and Connective Tissue Diseases (400)
Carboplatin (642) · Cisplatin (454) · Pemetrexed (450) · Paclitaxel (331) · Docetaxel (303) · pembrolizumab (299) · Gemcitabine (244) · Radiotherapy (212) · Erlotinib Hydrochloride (210) · Bevacizumab (200) · Nivolumab (190) · Etoposide (160) · durvalumab (141) · Drug Therapy (129) · osimertinib (127)
National Cancer Institute (NCI) (171) · Eli Lilly and Company (96) · M.D. Anderson Cancer Center (88) · Sun Yat-sen University (86) · Memorial Sloan Kettering Cancer Center (68) · Pfizer (51) · AstraZeneca (49) · Alliance for Clinical Trials in Oncology (46) · Novartis Pharmaceuticals (46) · Bristol-Myers Squibb (45) · Shanghai Pulmonary Hospital, Shanghai, China (42) · Tianjin Medical University Cancer Institute and Hospital (40) · SWOG Cancer Research Network (37) · Hoffmann-La Roche (35) · Fudan University (34)
United States (2117) · China (1098) · Spain (422) · France (390) · South Korea (365) · Italy (343) · Canada (333) · Germany (294) · United Kingdom (265) · Australia (225) · Taiwan (209) · Belgium (205) · Netherlands (192) · Poland (166) · Japan (163)
Mariano Provencio, MD (14) · Arun Rajan, M.D. (11) · Afshin Dowlati, MD (10) · Nasser Hanna, M.D. (10)
PMID 34393061, PMID 26291023, PMID 22586319, PMID 23442309, PMID 30207593, PMID 37934000, PMID 42820295, PMID 19692680, PMID 21502559, PMID 25175099, PMID 25490004, PMID 26104945, PMID 27130468, PMID 29293889, PMID 29658848, PMID 33241650, PMID 34405547, PMID 34408488, PMID 35537408, PMID 39462179, PMID 40341199, PMID 11698646, PMID 15771580, PMID 15800326, PMID 16014882, PMID 16204011, PMID 17075123, PMID 17167137, PMID 18565862, PMID 19901100, PMID 20516428, PMID 20636820, PMID 21502553, PMID 21784628, PMID 22325357, PMID 22327623, PMID 22333554, PMID 22452895, PMID 22473314, PMID 23533264, PMID 23816963, PMID 25349307, PMID 25403584, PMID 25497558, PMID 26148750, PMID 26712084, PMID 27718847, PMID 27745820, PMID 27825636, PMID 27863201
2023 (59), 2016 (36), 2017 (36), 2025 (34), U10CA031946 (31), U10CA032102 (30), 2018 (27), 2019 (27), 2015 (24), U10CA180888 (24), 2014 (23), 2008 (16), U10CA021115 (16), 2009 (14), P30CA022453 (14)